Humana (HUM)
(Delayed Data from NYSE)
$352.90 USD
-1.85 (-0.52%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $352.90 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$352.90 USD
-1.85 (-0.52%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $352.90 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum D VGM
Zacks News
Humana's (HUM) CenterWell Unit Plans to Expand in Tennessee
by Zacks Equity Research
Humana's (HUM) CenterWell business is likely to benefit from its promising plans to expand across middle Tennessee this year.
Here's Why Buying Brookdale (BKD) Stock is a Prudent Move Now
by Zacks Equity Research
For the second quarter, Brookdale (BKD) expects RevPAR growth to be in the range of 11.5-12%.
Here's Why Hold Strategy is Apt for The Joint (JYNT) Stock Now
by Zacks Equity Research
The Joint (JYNT) is expected to keep growing due to rising patient visits and new clinic openings.
The Joint (JYNT) Buys Wisconsin Regional Developer Zone Rights
by Zacks Equity Research
The Joint (JYNT) expects the Wisconsin region to hold a total of 53 clinics, of which 21 are currently operating.
U.S. Health Insurers Are Tumbling: Should You be Worried?
by Kaibalya Pravo Dey
Demand for procedures like hip and knee surgeries is rising, which will leave fewer premiums in hand after paying for the procedures for the health insurers.
Humana (HUM) Sees Insurance Costs at Upper Limit of Guidance
by Zacks Equity Research
Despite the rising demand for elective procedures, Humana (HUM) sticks to its earnings guidance.
Humana (HUM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $463.85, marking a +1.95% move from the previous day.
UnitedHealth (UNH) Falls 6.4% on Cost Woes of Resumed Surgeries
by Zacks Equity Research
UnitedHealth's (UNH) Optum Health unit is likely to witness higher utilization, especially in ambulatory surgery operations.
Humana (HUM) Wins Contract to Serve Oklahoma's Medicaid Members
by Zacks Equity Research
Humana (HUM) secures a contract from the OHCA and is likely to provide improved health outcomes for Medicaid members of Oklahoma.
Humana (HUM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Humana (HUM) closed at $513.34 in the latest trading session, marking a +0.69% move from the prior day.
Zacks Industry Outlook Highlights UnitedHealth Group, The Cigna Group, Humana, Centene Corporation and Molina Healthcare
by Zacks Equity Research
UnitedHealth Group, The Cigna Group, Humana, Centene Corporation and Molina Healthcare are part of the Zacks Industry Outlook article.
Humana (HUM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Humana (HUM) closed the most recent trading day at $509.83, moving +1.02% from the previous trading session.
5 HMO Industry Stocks to Watch as Technology Expenses Take a Toll
by Debasmita Chatterjee
The Medical-HMO industry is witnessing growth in customer base and an active M&A strategy. However, high technology expenses and medical personnel shortage raise concerns. UNH, CI, HUM, CNC and MOH are likely to navigate the industry storms.
Humana (HUM) Arm Reaches 250 Senior Primary Care Facilities
by Zacks Equity Research
Humana's (HUM) CenterWell business focuses on providing a better healthcare experience through clubbing primary care, home health and pharmacy services.
Humana (HUM) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Humana (HUM) closed at $520.78 in the latest trading session, marking a +1.09% move from the prior day.
CI or HUM: Which HMO Stock is Better Placed at the Moment?
by Zacks Equity Research
Cigna (CI) and Humana (HUM) are well-positioned to expand in the promising HMO space. Let's try to find out which one fares better via comparative evaluation.
Humana (HUM) Down 4.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Humana (HUM) in Your Portfolio
by Zacks Equity Research
Humana (HUM) remains well-poised for growth, attributable to a growing customer base, numerous contract wins and solid cash-generating abilities.
Humana (HUM) Teams Up With DME Entities to Boost Home Solutions
by Zacks Equity Research
These partnerships will equip Humana (HUM) with the means to deploy advanced clinical programs that can reduce hospitalizations for the members.
Here's Why Humana (HUM) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Select Medical (SEM) Q1 Earnings Top on Improving Profitability
by Zacks Equity Research
Select Medical (SEM) expects revenues to be within the range of $6.5-$6.7 billion in 2023, indicating a rise of 4.8% from the 2022 figure of $6.3 billion.
Brokers Suggest Investing in Humana (HUM): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for Humana (HUM) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Molina Healthcare (MOH) Beats on Q1 Earnings, Ups '23 EPS View
by Zacks Equity Research
Molina Healthcare's (MOH) Q1 results reflect strong performance in the Medicaid and Medicare segments. Meanwhile, the elevated expense level partially offset the positives.
Tenet Healthcare's (THC) Q1 Earnings Beat, Shares Up 3.9%
by Zacks Equity Research
Tenet Healthcare's (THC) first-quarter 2023 results gain on increased patient volumes. Management presently expects adjusted EPS within $4.92-$6.09 in 2023, up from the prior view of $4.68-$5.85.
Humana (HUM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Humana (HUM) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.